SCHEMBL878648

SCHEMBL878648

Nc1cccc(Cl)c1-n1ncc2c(Cl)ncnc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.43
HSD17B10 Q99714 4/20 0.43
ALDH1A1 P00352 3/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
TSHR P16473 2/20 0.43
EGFR P00533 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2C19 P33261 1/20 0.43
PI4KA P42356 1/20 0.43
PI4K2B Q8TCG2 1/20 0.43
PI4K2A Q9BTU6 1/20 0.43
PI4KB Q9UBF8 1/20 0.43
MAPK14 Q16539 1/20 0.41
HTT P42858 4/20 0.41
NPSR1 Q6W5P4 2/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
BLM P54132 1/20 0.41
XDH P47989 5/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL839952 0.90 MAPK14 (0.47) KDM4EHSD17B10ALDH1A1MEN1KMT2A
SCHEMBL878657 0.86 MAPK14 (0.42) KDM4EHSD17B10ALDH1A1MEN1KMT2A
SCHEMBL838945 0.83 MAPK14 (0.41) KDM4EHSD17B10ALDH1A1MEN1KMT2A
SCHEMBL838279 0.83 GCK (0.44) KDM4EHSD17B10ALDH1A1MEN1KMT2A
SCHEMBL838384 0.80 GCK (0.46) KDM4EHSD17B10ALDH1A1MEN1KMT2A
SCHEMBL25342469 0.78 SLC2A1 (0.43) KDM4EHSD17B10ALDH1A1MEN1KMT2A
SCHEMBL838829 0.77 P2RX7 (0.46) KDM4EHSD17B10ALDH1A1MEN1KMT2A
SCHEMBL839210 0.77 GCK (0.47) KDM4EHSD17B10ALDH1A1MEN1KMT2A
SCHEMBL839501 0.75 MAPK14 (0.48) KDM4EHSD17B10ALDH1A1MEN1KMT2A
SCHEMBL839442 0.75 TP53 (0.46) KDM4EHSD17B10ALDH1A1MAPK14HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143263-B2 Therapeutic agents ASTRAZENECA AB (SE) 2012-03-27 US disclosed
US-20100093757-A1 THERAPEUTIC AGENTS 414 ASTRAZENECA AB (SE) 2010-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093757-A1 THERAPEUTIC AGENTS 414 GCK, GCKR, GPR119 KDM4E 3541/4885HSD17B10 1170/4885ALDH1A1 1918/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.